Africa: Development of Next-Generation Antimalarial Treatment Starts
[MMV] Basel -Novartis announced today that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV). Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation. This agreement sets out the terms and conditions for the development of KAF156 and its future availability to patients.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news